KPRX Kiora Pharmaceuticals
- 0.5700
- -0.0115-1.98%
- 0.5700
- 0.00000.00%
Kiora Pharmaceuticals News
Buy Rating on Kiora Pharmaceuticals Amid Strong Financials and Promising Clinical Trials
Express News | Kiora Pharmaceuticals Inc - Revenue Was $16.0 Mln for Q1 of 2024, Compared to No Revenue in Q1 of 2023
Express News | Kiora Pharmaceuticals Inc - Qtrly Shr $0.38
10-Q: Quarterly report
Earnings Flash (KPRX) KIORA PHARMACEUTICALS Posts Q1 Revenue $16M
07:03 AM EDT, 05/10/2024 (MT Newswires) -- Earnings Flash (KPRX) KIORA PHARMACEUTICALS Posts Q1 Revenue $16M
Kiora Pharmaceuticals Reports First Quarter Results; Update on Pipeline of Drugs Targeting Retinal Disease
Phase 2 trial for KIO-301 for the treatment of retinitis pigmentosa, in partnership with Théa Open Innovation, expected to be initiated in Q4 2024Phase 2 clinical trial for KIO-104 for retinal inflam
Kiora Pharmaceuticals to Present at The Citizens JMP Life Sciences Conference
Kiora Pharmaceuticals to Present at The Citizens JMP Life Sciences Conference May 08, 2024 7:00am EDT Download as PDF Encinitas, California--(Newsfile Corp.
Kiora Pharmaceuticals Reports Additional Clinical Data for KIO-301 Showing a Statistically Significant Increase in Brain Activity in the Visual Cortex in Patients With Retinitis Pigmentosa
Previously released ABACUS-1 clinical trial results reported KIO-301, a small molecule photoswitch, is safe, tolerable, and improved vision in patients with late-stage retinitis pigmentosa. Additional
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
GainersImmutep (NASDAQ:IMMP) stock increased by 15.5% to $2.9 during Wednesday's pre-market session. The market value of their outstanding shares is at $344.7 million. Syra Health (NASDAQ:SYRA) stock
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers180 Life Sciences (NASDAQ:ATNF) shares moved upwards by 7.4% to $2.04 during Tuesday's after-market session. The market value of their outstanding shares is at $1.7 million. ABVC BioPharma (NAS
Kiora Pharmaceuticals Secures Grant for Vision Test Validation
Kiora Pharmaceuticals Receives Grant From Choroideremia Research Foundation to Fund Novel Clinical Trial Endpoints for Inherited Retinal Diseases; Approval Granted to Initiate Clinical Validation Study
Kiora Pharmaceuticals to Present at Upcoming Investor Conferences
Express News | Kiora Pharmaceuticals Shares Are Trading Higher After the Company Announced That It Will Present Additional Data From Its ABACUS-1 Trial of KIO-301 in Retinitis Pigmentosa at the ARVO 2024 Annual Meeting
Analysts Offer Insights on Healthcare Companies: Altimmune (ALT), Kiora Pharmaceuticals (KPRX) and Actinium Pharmaceuticals (ATNM)
Express News | Kiora Pharmaceuticals to Present Additional Data From Its ABACUS-1 Trial Of KIO-301 in Retinitis Pigmentosa At ARVO 2024 Annual Meeting
Kiora Pharmaceuticals to Present Additional Data From Its ABACUS-1 Trial in Retinitis Pigmentosa at the ARVO 2024 Annual Meeting
Encinitas, California--(Newsfile Corp. - March 28, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") announced that additional data from the ABACUS-1 trial has been accept
Kiora Pharmaceuticals Price Target Maintained With a $2.00/Share by HC Wainwright & Co.
Kiora Pharmaceuticals Price Target Maintained With a $2.00/Share by HC Wainwright & Co.
Analysts Offer Insights on Healthcare Companies: Kiora Pharmaceuticals (KPRX) and Genmab (GMAB)
HC Wainwright & Co. Maintains Buy on Kiora Pharmaceuticals, Maintains $2 Price Target
HC Wainwright & Co. analyst Yi Chen maintains Kiora Pharmaceuticals with a Buy and maintains $2 price target.
Analysis
Price Target
No Data
